{"protocolSection": {"identificationModule": {"nctId": "NCT02121041", "orgStudyIdInfo": {"id": "14-0670"}, "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study", "officialTitle": "Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study"}, "statusModule": {"statusVerifiedDate": "2016-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-05"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-04-16", "studyFirstSubmitQcDate": "2014-04-21", "studyFirstPostDateStruct": {"date": "2014-04-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-25", "resultsFirstSubmitQcDate": "2016-10-25", "resultsFirstPostDateStruct": {"date": "2016-12-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-19", "lastUpdatePostDateStruct": {"date": "2017-02-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Anthony J Viera, MD, MPH", "investigatorTitle": "Distinguished Associate Professor, Family Medicine", "investigatorAffiliation": "University of North Carolina, Chapel Hill"}, "leadSponsor": {"name": "Anthony J Viera, MD, MPH", "class": "OTHER"}, "collaborators": [{"name": "North Carolina Translational and Clinical Sciences Institute", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension.", "detailedDescription": "The usual strategy for detecting hypertension-repeated office blood pressure (BP) measurements-is inefficient and inaccurate. When paired with ambulatory BP monitoring (ABPM), which takes a multitude of measurements over 24 hours, it is clear that office BP measurements may convey a falsely positive diagnosis known as white-coat hypertension. What is less well-known is that office BP measurements may also convey a falsely negative diagnosis termed masked hypertension (MH). That is, office BP may measure as normal, yet 24-hour ambulatory measurements show elevated BP. People with MH have cardiovascular risk that is similar to that of people with diagnosed hypertension, yet MH goes unrecognized, and therefore, untreated. Ultimately, identifying the best strategy for accurately detecting hypertension is vital to improving overall BP control and reducing cardiovascular events. Without a feasible ABPM strategy, MH will continue to go unrecognized and untreated.\n\nParticipants enrolled in the study will be randomized to either the usual care group or the ABPM-guided group. All participants will have a baseline ABPM. ABPM will be used to make a diagnosis and determine anti-hypertensive treatment in the ABPM-guided group only. Participants in the ABPM-guided group will have a follow-up ABPM in 2 months. All participants will have a final ABPM 4 months after enrollment."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Blood Pressure", "Ambulatory Blood Pressure Monitoring"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Usual Care", "type": "NO_INTERVENTION", "description": "Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care."}, {"label": "ABPM Guided", "type": "ACTIVE_COMPARATOR", "description": "Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.", "interventionNames": ["Drug: Amlodipine", "Drug: Chlorthalidone", "Drug: Losartan"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 mg or 10 mg", "armGroupLabels": ["ABPM Guided"], "otherNames": ["Norvasc"]}, {"type": "DRUG", "name": "Chlorthalidone", "description": "Chlorthalidone 12.5 mg or 25 mg", "armGroupLabels": ["ABPM Guided"], "otherNames": ["Thalitone"]}, {"type": "DRUG", "name": "Losartan", "description": "Losartan 50 mg or 100 mg", "armGroupLabels": ["ABPM Guided"], "otherNames": ["Cozaar"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "24 Hour Blood Pressure Average at the End of 4 Month Participation.", "timeFrame": "Participants will be on study average of 4 months."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 30 years and \u2264 65 years\n* Most recent (within 14 days) clinic systolic BP 126-150 mm Hg\n* Able/willing to wear a BP monitor for 24 hours on multiple occasions\n* Able/willing to take daily anti-hypertensive medication if indicated\n* Able to read and speak English\n\nExclusion Criteria:\n\n* Pregnant or trying to become pregnant\n* Known heart disease\n* History of persistent atrial fibrillation\n* Currently taking antihypertensive medication\n* Currently taking Simvastatin \\> 20mg daily\n* Clinician recommends against participation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Anthony J Viera, MD, MPH", "affiliation": "University of North Carolina", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of North Carolina", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Usual Care", "description": "Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care."}, {"id": "FG001", "title": "ABPM Guided", "description": "Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.\n\nAmlodipine: Amlodipine 5 mg or 10 mg\n\nChlorthalidone: Chlorthalidone 12.5 mg or 25 mg\n\nLosartan: Losartan 50 mg or 100 mg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Usual Care", "description": "Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care."}, {"id": "BG001", "title": "ABPM Guided", "description": "Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.\n\nAmlodipine: Amlodipine 5 mg or 10 mg\n\nChlorthalidone: Chlorthalidone 12.5 mg or 25 mg\n\nLosartan: Losartan 50 mg or 100 mg"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "28"}]}], "measures": [{"title": "Age, Customized", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.6", "spread": "12"}, {"groupId": "BG001", "value": "49.2", "spread": "10"}, {"groupId": "BG002", "value": "48.4", "spread": "11"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "24 Hour Blood Pressure Average at the End of 4 Month Participation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Participants will be on study average of 4 months.", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care."}, {"id": "OG001", "title": "ABPM Guided", "description": "Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.\n\nAmlodipine: Amlodipine 5 mg or 10 mg\n\nChlorthalidone: Chlorthalidone 12.5 mg or 25 mg\n\nLosartan: Losartan 50 mg or 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "134", "spread": "11"}, {"groupId": "OG001", "value": "132", "spread": "10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Usual Care", "description": "Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 1, "otherNumAtRisk": 14}, {"id": "EG001", "title": "ABPM Guided", "description": "Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.\n\nAmlodipine: Amlodipine 5 mg or 10 mg\n\nChlorthalidone: Chlorthalidone 12.5 mg or 25 mg\n\nLosartan: Losartan 50 mg or 100 mg", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 1, "otherNumAtRisk": 14}], "otherEvents": [{"term": "electrolyte", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Abnormal electrolyte level", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Anthony Viera", "organization": "UNC Chapel Hill", "email": "viera@med.unc.edu", "phone": "984-974-4636"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000002752", "term": "Chlorthalidone"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5993", "name": "Chlorthalidone", "asFound": "Oropharyngeal", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}